This clinical trial focuses on patients with pancreatic cancer who are receiving a combination chemotherapy treatment called FOLFIRINOX. This treatment consists of four medications: fluorouracil, oxaliplatin, irinotecan, and calcium folinate. These medications are given through an intravenous infusion directly into the bloodstream.
The purpose of this study is to evaluate and improve the dosing of fluorouracil, one of the main components of FOLFIRINOX treatment. The study will measure how the body processes this medication and determine whether personalizing the dose for each patient leads to better results than using standard dosing based on body surface area.
The study is divided into two parts. In the first part, patients will receive standard doses of FOLFIRINOX, and researchers will measure the amount of medication in their blood. In the second part, patients will receive personalized doses of fluorouracil based on their individual needs. Throughout the study, patients will need to provide blood samples to measure medication levels. The total treatment period may last up to 24 months.



The Netherlands